1 Min Read
* CFO SAYS SEES IT IS STILL EARLY TO ASSESS IMPACT OF COMPETITOR ROCHE’S HEMLIBRA ON HEMOPHILIA FRANCHISE Further company coverage: (Reporting By London Bureau)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.